NCT07117227
Validation of RCC Predicting Model With Emulated-target Trial
Recruiting · Not specified · Peking University Third Hospital · registry updated 2026-04-14
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
This single-center study utilizes real-world data (2012-2024) from 4700 renal cell carcinoma (RCC) patients at Peking University Third Hospital to: (1) Develop and validate a prognostic prediction model specifically for RCC patients, including those with venous tumor thrombus (VTT); (2) Compare the performance of this new model against existing RCC prediction models in both the overall RCC cohort and the VTT subgroup; (3) Employ an emulated target trial (ETT) methodology to evaluate whether risk-stratified treatment based on the prediction model (grouping patients as high/medium/low risk) improves survival outcomes .
Inclusion
- Adults ≥18 years of age;
- Diagnosis of primary renal cell carcinoma before and during the surgery;
- Received radical nephrectomy/nephron-sparing surgery.
Exclusion
- Subjects with severely missing clinical information;
- History of other malignant tumors.
- Recurrence observed before first postoperative follow-up.
- Discontinue the adjuvant treatment within in the first two course because of severe adverse react.